<DOC>
	<DOCNO>NCT00415740</DOCNO>
	<brief_summary>The purpose study assess safety bioequivalence single oral dose carbidopa+levodopa+entacapone combination versus single oral dose carbidopa+levodopa combination plus single oral dose entacapone fast condition healthy volunteer .</brief_summary>
	<brief_title>Bioequivalence Study Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Healthy male female subject age 18 55 year age include , good health At Screening , Baseline , vital sign ( systolic diastolic blood pressure pulse rate ) assess subject rest least five ( 5 ) minute , require three ( 3 ) minute stand position . Vital sign within normal range Body mass index ( BMI ) within range 18 27 weigh least 50 kg Female subject must undergo hysterectomy , must postmenopausal . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Receiving monoamine oxidase ( MAO ) inhibitor within 28 day prior first dose A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result History clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . Significant illness within two week prior dose Subjects , completion study , would donate excess : 500 mL blood 14 day ; 1500 mL blood 180 day ; 2500 mL blood 1 year . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Women child bear potential ( WOCBP ) History presence glaucoma suspicious undiagnosed skin lesion Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>bioavailability</keyword>
	<keyword>carbidopa</keyword>
	<keyword>levodopa</keyword>
	<keyword>entacapone</keyword>
	<keyword>fast</keyword>
	<keyword>Healthy volunteer study</keyword>
</DOC>